NewAmsterdam Pharma Co N.V. (NAMS) is a pre-commercial late-stage biopharma with a single asset (obicetrapib, a CETP inhibitor) and no marketed products as of March 31, 2026. Under a liquidation lens, the balance sheet is overwhelmingly composed of financial assets—cash, cash equivalents, restricted cash, and marketable securities—which are the only balance-sheet lines that recover at or near par. Total assets are $732.6M; total liabilities are $67.4M (all current), leaving reported book equity of $665.2M. However, the MFFAIS-derived cash liquidation value (CLV) of $390.2M versus book equity of $665.2M reflects the haircut applied to non-cash assets and the face-value treatment of liabilities. The gap is driven primarily by the $50.2M warrant derivative liability (fair-value, mark-to-market) and accrued liabilities carried at face value, but more structurally by the company's $810.8M accumulated deficit and fully reserved deferred tax assets—neither of which reduces the liquidation liability stack. The dominant recovery driver is the liquid asset pool: cash and cash equivalents of $457.6M, restricted cash of $1.3M, current marketable securities of $178.5M, and non-current marketable securities of $71.2M, aggregating approximately $708.6M in financial assets. Applying a 100% haircut to cash/restricted cash and a typical 95-100% haircut to US government/agency marketable securities (per filing description), liquid asset recovery is approximately $705-710M. Against total liabilities of $67.4M at face value (all current, no long-term debt), the implied net recovery is approximately $638-643M. The gap versus CLV ($390.2M) in MFFAIS likely reflects their treatment of the warrant derivative liability ($50.2M) at face value and adjustments for off-balance-sheet cancellation fee exposure ($38.4M disclosed in Note 12 as maximum CRO/CMO cancellation fees, untangled in XBRL only as a custom tag). PP&E is de minimis ($379K net), intangibles negligible ($375K), and operating lease ROU is immaterial ($21K). No goodwill, no pension obligation, no long-term debt. From December 31, 2025 to March 31, 2026, cash at period-end moved from $491.3M to $458.9M (per cash flow statement), a decrease of approximately $32.4M, reflecting net operating cash burn of $30.6M plus net investing outflows of $11.5M, partially offset by $11.1M from financing (option exercises and warrant exercises). The warrant liability ($50.2M at quarter-end) remains the largest single non-trade liability and is classified entirely as current. The filing discloses that CRO/CMO maximum cancellation fees total $38.4M as of March 31, 2026 (versus $39.1M at December 31, 2025); this contingent liability does not appear on the balance sheet but would reduce liquidation proceeds if wind-down triggered cancellation. The prior filing (10-K for year ended December 31, 2025) is used as the comparison period.
▼ Community Notes